IP Library Granted Patent US 10,829,745
Granted Patent B2
US 10,829,745 · App. 16/103,275 · Granted Nov 10, 2020

In vitro methods for processing lignin and other aromatic compounds

Inventors: Timothy James Donohue (Middleton, WI); Daniel Leo Gall (Madison, WI); Wayne S. Kontur (Madison, WI); Hoon Kim (Madison, WI); John Ralph (Madison, WI); Daniel R. Noguera (Madison, WI); Brian Fox (Madison, WI); Craig Bingman (Fitchburg, WI)
Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
C12N9/1088C12P7/22C12P7/26C12N9/88C12Y114/16005C12Y205/01018
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,829,745
App. No.
16/103,275
Granted
Nov 10, 2020
Kind
B2
Abstract

Enzymes for depolymerizing lignin. The enzymes include dehydrogenases, β-etherases, and glutathione lyases. The dehydrogenases can comprise one or more or LigD, LigO, LigN, and LigL. The β-etherases can comprise one or more of LigE, LigF, LigP, and BaeA. The glutathione lyases can comprise any one or more of LigG and a number of non-stereospecific, optionally recombinant glutathione lyases derived from Sphingobium sp. SYK-6, Novosphingobium aromaticivorans, Escherichia coli, Streptococcus sanguinis, Phanerochaete chrysosporium , and other microorganisms. The enzymes can be combined in compositions and/or used in methods of processing lignin or other aromatic compounds in vitro.

Claims (74)

1. A method of processing lignin, comprising contacting lignin comprising β-O-4 ether linkages in vitro with:

a dehydrogenase comprising at least one of LigD, LigO, LigN, and LigL;

a β-etherase comprising at least one of LigE, LigF, LigP, and an enzyme comprising a first polypeptide having an amino acid sequence of SEQ ID NO:40 or an amino acid sequence at least about 95% identical thereto and a second polypeptide having an amino acid sequence of SEQ ID NO:42 or an amino acid sequence at least about 95% identical thereto; and

a non-stereospecific glutathione lyase comprising an amino acid sequence at least about 80% identical to any of:

SEQ ID NO:18 (NaGST Nu );

residues 21-313 of SEQ ID NO:20 (recombinant NaGST Nu );

SEQ ID NO:22 (SYK6GST Nu );

residues 21-324 of SEQ ID NO:24 (recombinant SYK6GST Nu );

SEQ ID NO:26 (ecYghU);

residues 21-313 of SEQ ID NO:28 (recombinant ecYghU); and

SEQ ID NO:32 (ssYghU),

wherein the non-stereospecific glutathione lyase comprises at least four of:

threonine or a conservative variant of threonine at a position corresponding to position 51 of SEQ ID NO:18 (NaGST Nu );

asparagine or a conservative variant of asparagine at a position corresponding to position 53 of SEQ ID NO:18 (NaGST Nu );

glutamine or a conservative variant of glutamine at a position corresponding to position 86 of SEQ ID NO:18 (NaGST Nu );

lysine, a conservative variant of lysine, arginine, or a conservative variant of arginine at a position corresponding to position 99 of SEQ ID NO:18 (NaGST Nu );

isoleucine or a conservative variant of isoleucine at a position corresponding to position 100 of SEQ ID NO:18 (NaGST Nu );

glutamate or a conservative variant of glutamate at a position corresponding to position 116 of SEQ ID NO:18 (NaGST Nu );

serine, threonine, a conservative variant of serine, or a conservative variant of threonine at a position corresponding to position 117 of SEQ ID NO:18 (NaGST Nu ); and

arginine or a conservative variant of arginine at a position corresponding to position 177 of SEQ ID NO:18 (NaGST Nu ).

2. The method of claim 1 , wherein the non-stereospecific glutathione lyase comprises an amino acid sequence at least about 85% identical to any of:

SEQ ID NO:18 (NaGST Nu );

residues 21-313 of SEQ ID NO:20 (recombinant NaGST Nu );

SEQ ID NO:22 (SYK6GST Nu );

residues 21-324 of SEQ ID NO:24 (recombinant SYK6GST Nu );

SEQ ID NO:26 (ecYghU);

residues 21-313 of SEQ ID NO:28 (recombinant ecYghU); and

SEQ ID NO:32 (ssYghU).

3. The method of claim 1 , wherein the non-stereospecific glutathione lyase comprises an amino acid sequence at least about 90% identical to any of:

SEQ ID NO:18 (NaGST Nu );

residues 21-313 of SEQ ID NO:20 (recombinant NaGST Nu );

SEQ ID NO:22 (SYK6GST Nu );

residues 21-324 of SEQ ID NO:24 (recombinant SYK6GST Nu );

SEQ ID NO:26 (ecYghU); and

residues 21-313 of SEQ ID NO:28 (recombinant ecYghU).

4. The method of claim 1 , wherein the non-stereospecific glutathione lyase comprises an amino acid sequence at least about 95% identical to any of:

SEQ ID NO:18 (NaGST Nu );

residues 21-313 of SEQ ID NO:20 (recombinant NaGST Nu );

SEQ ID NO:22 (SYK6GST Nu );

residues 21-324 of SEQ ID NO:24 (recombinant SYK6GST Nu );

SEQ ID NO:26 (ecYghU); and

residues 21-313 of SEQ ID NO:28 (recombinant ecYghU).

5. The method of claim 1 , wherein the non-stereospecific glutathione lyase comprises at least seven of:

asparagine or a conservative variant of asparagine at a position corresponding to position 25 of SEQ ID NO:18 (NaGST Nu );

threonine or a conservative variant of threonine at a position corresponding to position 51 of SEQ ID NO:18 (NaGST Nu );

asparagine or a conservative variant of asparagine at a position corresponding to position 53 of SEQ ID NO:18 (NaGST Nu );

glutamine or a conservative variant of glutamine at a position corresponding to position 86 of SEQ ID NO:18 (NaGST Nu );

lysine, a conservative variant of lysine, arginine, or a conservative variant of arginine at a position corresponding to position 99 of SEQ ID NO:18 (NaGST Nu );

isoleucine or a conservative variant of isoleucine at a position corresponding to position 100 of SEQ ID NO:18 (NaGST Nu );

glutamate or a conservative variant of glutamate at a position corresponding to position 116 of SEQ ID NO:18 (NaGST Nu );

serine, threonine, a conservative variant of serine, or a conservative variant of threonine at a position corresponding to position 117 of SEQ ID NO:18 (NaGST Nu );

tyrosine or a conservative variant of tyrosine at a position corresponding to position 166 of SEQ ID NO:18 (NaGST Nu );

arginine or a conservative variant of arginine at a position corresponding to position 177 of SEQ ID NO:18 (NaGST Nu ); and

tyrosine or a conservative variant of tyrosine at a position corresponding to position 224 of SEQ ID NO:18 (NaGST Nu ).

6. The method of claim 1 , wherein the contacting occurs in the presence of a glutathione (GSH) reductase that catalyzes reduction of glutathione disulfide (GSSG).

7. The method of claim 6 , wherein the GSH reductase comprises an amino acid sequence at least about 95% identical to SEQ ID NO:38 (AvGR).

8. The method of claim 1 , wherein the contacting releases at least one of a monomeric phenylpropanoid unit and a monomeric flavone.

9. The method of claim 1 , wherein the contacting releases at least one of a monomeric guaiacyl phenylpropanoid unit, a monomeric syringyl phenylpropanoid unit, a monomeric p-hydroxyphenyl phenylpropanoid unit, and a monomeric tricin unit.

10. The method of claim 1 , wherein the lignin comprises an average molecular weight (MW) of from about 600 to about 20,000.

11. The method of claim 1 , wherein the dehydrogenase comprises at least one of LigD and LigO and at least one of LigL and LigN.

12. The method of claim 1 , wherein the dehydrogenase comprises LigD and LigN.

13. The method of claim 1 , wherein the β-etherase comprises LigF and at least one of LigE, LigP, and the enzyme comprising the first polypeptide having the amino acid sequence of SEQ ID NO:40 or the amino acid sequence at least about 95% identical thereto and the second polypeptide having the amino acid sequence of SEQ ID NO:42 or the amino acid sequence at least about 95% identical thereto.

14. The method of claim 1 , wherein the β-etherase comprises LigF and LigE.

15. The method of claim 1 , wherein the non-stereospecific glutathione lyase comprises an amino acid sequence at least about 95% identical to SEQ ID NO:18 (NaGST Nu ).

16. The method of claim 1 , wherein:

the dehydrogenase comprises at least one of LigD and LigO and at least one of LigL and LigN;

the β-etherase comprises LigF and at least one of LigE, LigP, and the enzyme comprising the first polypeptide having the amino acid sequence of SEQ ID NO:40 or the amino acid sequence at least about 95% identical thereto and the second polypeptide having the amino acid sequence of SEQ ID NO:42 or the amino acid sequence at least about 95% identical thereto;

the non-stereospecific glutathione lyase comprises an amino acid sequence at least about 95% identical to SEQ ID NO:18 (NaGST Nu ); and

the contacting occurs in the presence of a glutathione (GSH) reductase that catalyzes reduction of glutathione disulfide (GSSG) and comprises an amino acid sequence at least about 95% identical to SEQ ID NO:38 (AvGR).

17. The method of claim 1 , wherein:

the dehydrogenase comprises LigD and LigN;

the β-etherase comprises LigF and LigE;

the non-stereospecific glutathione lyase comprises an amino acid sequence at least about 95% identical to SEQ ID NO:18 (NaGST Nu ); and

the contacting occurs in the presence of a glutathione (GSH) reductase that catalyzes reduction of glutathione disulfide (GSSG) and comprises an amino acid sequence at least about 95% identical to SEQ ID NO:38 (AvGR).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2022
From: GALL, DANIEL; KONTUR, WAYNE; KIM, HOON; RALPH, JOHN; DONOHUE, TIMOTHY; NOGUERA, DANIEL; FOX, BRIAN; BINGMAN, CRAIG
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 059708/0459 →
CONFIRMATORY LICENSE Recorded Mar 26, 2019
From: UNIVERSITY OF WISCONSIN-MADISON
To: UNITED STATES DEPARTMENT OF ENERGY
Reel/Frame 050153/0042 →
Continuity (2)
Provisional Application 62545214 · Aug 14, 2017
Related Publication 20190048329A1 · Feb 14, 2019